Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM. [electronic resource]
Producer: 20151203Description: 570-7 p. digitalISSN:- 1468-1331
- Adult
- Exercise Test
- Female
- Humans
- Immunologic Factors -- administration & dosage
- Male
- Middle Aged
- Mobility Limitation
- Multiple Sclerosis, Relapsing-Remitting -- drug therapy
- Natalizumab -- administration & dosage
- Outcome Assessment, Health Care
- Prospective Studies
- Retrospective Studies
- Severity of Illness Index
- Walking -- physiology
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.